Back

COPD Research Study

Official Title

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Study Details

This study will evaluate the efficacy and safety of an injectable medication compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.

Principal Investigator

Dr. James Krings

IRB Number

202306050

Eligibility

1. Participants must be between 40 and 80 years of age
2. Participants must have diagnoses of COPD (for at least 1 year) and must have had two or more COPD exacerbations in the last year
3. Participants must be a current or former smoker

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back